AnthonyRathMediaResearchWk#9~#5VoiceOver

The TTC has three main components: the targeting module, which can be an antibody or small molecule bound to the HOPO chelator; serum 227; and the cold and hot IMPs, which are the antibody chelator conjugator and the labeled serum ACC, respectively. The targeting molecules are carefully chosen based on surface proteins and receptors associated with cancer cells. Each new targeting molecule represents a new drug, so there is a platform of targeted serum conjugates in development. The TTC is consistent of three key components, as described in detail in the introduction module. There is the targeting module, for example, an antibody peptide or small molecule that is bound to the HOPO chelator via a lysine binding, and of course, serum 227. Although referred to as a hot IMP and cold IMP, this does not relate to temperature. Cold IMP is the antibody chelator conjugator, or ACC. Hot IMP is a serum labeled ACC. For the purposes of simplicity, in this module, we have used antibodies and diagrams and terminology for the targeting module. While developing the TTC platform, these targeting molecules will be both antibodies and small molecules. The targeting molecules are carefully selected based on surface proteins and receptors associated with specific cancer cell lines that are typically overexpressed on the cancer cell surface. Every new targeting part means a new drug. Thus, we have an entire platform of targeted serum conjugates in the pipeline.